Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

Exanta

 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2005
2005
For decades, the standards of antithrombotic therapy have been heparin and coumarin compounds, primarily warfarin (1). Other… Expand
Is this relevant?
2005
2005
Thrombosis is the leading cause of death from heart attacks and strokes. Warfarin (coumadin), the only marketed oral… Expand
Is this relevant?
Review
2004
Review
2004
It is rare for any drug introduced more than 50 years ago to remain unsurpassed today; yet the oral prevention and treatment of… Expand
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
Is this relevant?
2004
2004
INTRODUCTION The effect of the oral direct thrombin inhibitor (DTI) ximelagatran (Exanta, AstraZeneca) on the endogenous thrombin… Expand
Is this relevant?
2004
2004
Background Ximelagatran (Exanta™, AstraZeneca), an oral direct thrombin inhibitor for the prevention and treatment of… Expand
Is this relevant?
Review
2004
Review
2004
The oral direct thrombin inhibitor ximelagatran (Exanta, AstraZeneca) is rapidly absorbed, is efficiently bioconverted to the… Expand
Is this relevant?
Review
2003
Review
2003
The oral direct thrombin inhibitor (oral DTI) ximelagatran (Exanta, AstraZeneca) is rapidly absorbed and bioconverted to its… Expand
Is this relevant?
2003
2003
  • Owen Glynn
  • International journal of clinical practice
  • 2003
  • Corpus ID: 36614347
The phase III trial EXPRESS was a randomised, double-blind comparison of two anticoagulant therapies used as prophylaxis against… Expand
Is this relevant?
Review
2003
Review
2003
There are many well-known drawbacks associated with the currently used antithrombotic agents, warfarin, heparin, and low… Expand
Is this relevant?
Review
2002
Review
2002
  • Rob Hopfner
  • Current opinion in investigational drugs
  • 2002
  • Corpus ID: 28849960
AstraZeneca (formerly Astra) is developing ximelagatran, an orally active thrombin inhibitor and prodrug of melagatran, for the… Expand
Is this relevant?